Two metabolites were isolated from the urine of patients taking phenylbutazone by Burns, Rose, Goodwin, Reichenthal, Horning, and Brodie (1955) ; these metabolites were found to be identical with two pyrazole compounds synthesized in Switzerland by Pfister and Haffliger (1957) and Denss, Hifliger, and Goodwin (1957) , which were called respectively G27 202 (p-hydroxyphenylbutazone) and G28 315, the latter being a potent uricosuric agent. Experiment had shown that G27 was an antiinflammatory agent equal in potency to phenylbutazone but producing few of the side-effects commonly associated with this drug. When G27 became available for clinical trial, it was decided to test its effect in rheumatoid arthritis. Hart and Burnley (1959) have reported its effects in a number of conditions, Vaughn, Howell and Kiem (1959) have reported the results of a trial in which it was compared with steroids, aspirin, and phenylbutazone in patients with rheumatoid arthritis.
The present investigation has been conducted as a double-blind trial, using G27 and a bland tablet; in this way it was hoped to show whether G27 possessed anti-rheumatic as well as anti-inflammatory properties or whether it was merely another comparatively non-toxic analgesic.
Method Thirty patients were taken, all suffering from rheumatoid arthritis, as defined by the American Rheumatism Association (Steinbrocker, Traeger, and Batterman, 1949) of varying severity and duration.
Fifteen received tablets of G27 (200 mg. twice daily with or after food), and the other fifteen received bland tablets identical in size, shape, and colour, and supplied in identical bottles. The allocation and distribution of the tablets weas completely randomized, and this, together with the dispensing of the tablets, was carried out by colleagues in no way associated with the trial. The code was held by another doctor in the clinic, so that in the event of an emergency (as for example, the suspicion of agranulocytosis), advice with regard to treatment was available without upsetting the trial as a whole. In fact, no such emergency arose during the trial. The patients were asked if they would co-operate in the trial of a new drug which might or might not help them and which might produce side-effects; they were not told that two different sets of identical tablets were being used, nor were they told that at the end of the trial period of 6 weeks those taking the control tablets would be automatically switched to G27. In this way, it was hoped to eliminate any possible bias in the patient towards a new drug.
No patients who were being given steroids or gold injections were included in the trial. The patients were asked during the 6-week trial not to take any other tablets whatsoever unless they felt that their condition was deteriorating, in which case they were asked to take aspirin, and to note the amount taken each day. As far as possible they were seen for clinical assessment and blood test each week. For the assessment of disease activity, etc., the three worst joints, as indicated by the patient, were taken as representative of the whole, and tenderness, pain, and swelling, were estimated on these joints alone throughout the trial.
Results
The trial was kept up until every patient had completed 6 weeks' treatment and all the blood tests and blood level estimations were available. Five patients in all failed to complete the trial. One in the G27 group developed pneumonia after 2 weeks, up to which time he had reported good progress, and four in the control group, all of whom tolerated the tablets for 3 or 4 weeks, asked to be allowed to go back to the previous treatment because they felt their condition to be deteriorating. Three of these four patients were, in fact, persuaded to continue for a further week, and during that week they were changed to G27 from the control tablets without their knowledge; two reported great improvement during that week and have since continued with G27 with benefit. A factor seldom regarded as statistically significant but one which is clinically interesting, is the patient's opinion of the treatment. When it is borne in mind that none of these patients knew that control tablets were included in the trial, it is interesting to find that twelve of the fifteen on G27 said they felt better at the end of the trial, and that twelve of the fifteen controls said that they felt the same or worse.
Complications.-In view of the multiplicity of complications recorded when phenylbutazone is used, even the slightest unusual feature noted by the patients was recorded, and they were directly questioned about the side-effects usually said to be associated with phenylbutazone. None of the sideeffects noted were persistent, and the majority cleared by the time the patient attended in the following week. At no time was it necessary to consider stopping the drug because of side-effects. Diarrhoea and loose motions and occasional transient pruritus seemed to be the side-effects most commonly complained of, but they all cleared rapidly in spite of continued treatment at the same dosage. A greater variety of side-effects was found amongst the control group (Table II) . 6 weeks is far too short a period in which to decide whether side-effects result from the use of a new drug, but subsequent experience confirms the impressions already reported by Hart and Burnley (1959) and Vaughan and others (1959) that G27 appears to be free from serious side-effects. group.bmj.com on June 24, 2017 -Published by http://ard.bmj.com/ Downloaded from G27 patients, and in this way a check was available to show whether any patient had been given the wrong tablets. In fact, no G27 was found in the blood of the controls. The blood picture showed little difference between the two groups, and there was little variation from week to week; at no stage did a fall occur in the circulating polymorphonuclear leucocytes. Liver function tests, although by no means normal in themselves, especially with regard to thymol turbidity and zinc sulphate levels at the start of the trial, showed no difference between the groups after 6 weeks.
With regard to the blood levels of G27, the average level when 400 mg. daily was taken was 11 -2 mg. per cent. (range 6 to 17 mg. per cent.). This is high when compared with blood Butazolidin levels and suggests a good rate of absorption from the gut. From results obtained since the conclusion of the trial, it appears that G27 is rapidly both absorbed and excreted; a level as high as 18 mg. per cent. was registered 48 hrs after starting the drug, and on another occasion the level had dropped to 2 mg. per cent. within 48 hrs of stopping it. One of the difficulties encountered in estimating G27 levels isthat there is very little difference between the wave bands of G27 and Butazolidin, but as it is unlikely that both drugs will be administered at the same time, and provided 2 to 3 weeks is allowed for any Butazolidin to clear from the blood stream before the G27 levels are estimated, there is little likelihood of confusion. Codeine and salicylates when given in a a large enough dosage may also lead to confusion, but the wave bands of all these drugs are quite distinct.
Correlating the height of the blood level and the incidence of side-effects showed no obvious trend towards the assumption that the higher the level, the more frequent the complications, but a much greater series and much higher levels must be obtained before this can be proven. However, in the three cases that showed levels of above 15 mg. per cent. no side-effects were reported at all.
Summary
The results are reported of a blind trial of G27 202. Half of thirty patients suffering from rheumatoid arthritis were given 400 mg. G27 202 daily, and half were given placebo tablets for a period of 6 weeks. There was definite improvement in strength of grip, morning stiffness, pain, tenderness, and swelling in those taking G27 202 in comparison with those taking the control tablets. It is suggested, in view of these findings, that G27 202 has analgesic and anti-inflammatory properties equal to those of phenylbutazone but not associated with any of the side-effects seen with the latter drug. The fact that the erythrocyte sedimentation rate showed no alteration suggests that G27 202 has little if any anti-rheumatic potency, but it is felt that this drug should be seriously considered as an alternative therapeutic agent in the treatment of rheumatoid arthritis.
I should like to express my thanks to Dr. W. Stoddart for his help and encouragement, to Dr. A. L. Miller and his Staff both at the Middlesex Hospital and the Arthur Stanley Institute for their help and co-operation with blood investigations and levels, and to Messrs. Geigy Ltd. for the generous supplies of G27 202 used throughout the trial. DISCUSSION DR. 0. SAVAGE (London) congratulated Dr. Cardoe on his report. The fact that this was a carefully planned trial with double blind control emphasized how few objective measurements we had in rheumatoid arthritis.
Morning stiffness, pain, and tenderness were subjective, and even the grip test was not entirely objective. He felt that, with an increasing number of drugs available for the treatment of rheumatoid arthritis, the question which was the best would remain uncertain until the objective methods of assessing the disease were improved. DR. J. J. R. DUTHIE (Edinburgh) asked whether G27 202 was a better analgesic than aspirin.
Another speaker asked if temperatures were taken. PROF. S. J. HARTFALL (Leeds) asked if there were more toxic reactions amongst treated than amongst control cases, and whether the number of placebo reactors had been determined.
DR. CARDOE replied that G27 202 was about as good an analgesic as aspirin or phenylbutazone, but not so efficient as aspirin as an anti-rheumatic agent. Temperatures had not been taken. Erythrocyte sedimentation rates remained abnormal in both the treated and the control groups.
Placebo reactors had not been especially looked for, but he had noted that oral ulcers, usually considered to be a toxic effect of phenylbutazone, had been equally frequent in each group. DR. M. F. MCMAHON (Cork) said that he had conducted a controlled trial of G27 202 in 120 patients and had noted that mouth ulcers and pruritus were more common amongst the controls. In his series, two out of forty, who had both drugs, asked to stop G27 202 and to take phenylbutazone instead, because they considered it more effective.
